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ABSTRACT 
Overwhelming infection represents a significant hazard in 
patients following splenectomy or in functional asplenia due to a 
variety of disorders. Defects in the alternative complement pathway 
\ 
(ACP) activity have been suggested in several of these disorders. 
In the present study, nonspecific opsonic activity in Hodgkin's 
disease patients was investigated at various intervals postsplenec-
tomy. A few patients were evaluated prior to surgery. This activity 
was measured indirectly by PMN chemiluminescence (CL) produced as the 
leukocytes phagocytize zymosan particles opsonized in chelated sera 
from patients and controls. ACP opsonic activity as measured by 
the CL produced was slightly depressed 10-31 days postoperatively 
but usually returned to normal levels one month after surgery in 
adults. In three adolescent patients, decreased opsonic activity 
persisted. No such depression was evident in nonchelated sera. 
Factor Band IgM levels did not correlate with the depressed activity. 
These data suggest that nonspecific opsonic activity of the ACP is 
transiently decreased in Hodgkin's disease patients following 
splenectomy; and, component(s) other than Factor Band IgM may be 
responsible for this abnormality. Additional investigations are 
indicated, however, to confirm these trends and correlate them with 
the propensity to develop overwhelming postsplenectomy infections. 
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CHAPTER 1 
INTRODUCTION 
It has been shown repeatedly that splenectomized individuals 
have an increased incidence of overwhelming infections (4, 8, 16, 
18, 20). Sickle cell anemia patients also have increased suscepti-
bility to sepsis (11, 12, 21). Many theories have attempted to 
describe the abnormality which is responsible for such patients' 
susceptibility to organisms such as Streptococcus pneumoniae, 
Es and Hemophilus influenzae (12, 16, 18). As the 
spleen is considered to be the largest reticuloendothelial organ in 
the body, it is readily apparent that the loss or dysfunction of 
this organ should have some effect on the body's ability to clear 
bacteria from the blood stream. Many theories concerning overwhelm-
ing infection after the removal or dysfunction of the spleen have 
focused on aspects of the processes of bacterial clearance. 
An important aspect of the body's defense mechanism results 
from phagocytosis and intracellular killing by the cells of the 
reticuloendothelial systems. Bacterial clearance by the phagocytes 
has been recognized to occur in four phases which include chemotaxis 
(the migration of the phagocyte toward the bacteria resulting from 
the attraction by chemotactically active substances), opsonization 
(the coating of the bacteria with substances which promote ingestion 
by the phagocyte), actual ingestion (the bacteria is taken inside the 
2 
phagocyte and stored in a vacuole), and degranulation (the lysosomal 
granules of the phagocyte release their contents into the vacuole 
which aids in killing of the bacteria) (19). The second phase 
opsonization, has been theorized to have several mechanisms depend-
ing upon the type of particle as well as the immune status of 
the host (19). Specific anticapsular antibody may act alone or in 
conjunction with the classical complement pathway to opsonize 
particles. In the absence of specific antibody, the alternative 
complement pathway (ACP) may act as a nonspecific opsonin (14, 19). 
Splenectomized patients are often infected with organisms 
such as S. pneumoniae to which they may not possess high levels of 
specific antibody (12, 16, 18). 1Vhen such antibody is not present, 
precise functioning of the alternative complement pathway (ACP) is 
imperative (12). Several investigators have reported defects in the 
ACP in splenectomized patients which may contribute to the increased 
incidence of overwhelming infection (11, 21). These abnormalities 
have been attributed to decreased levels of functioning Factor 
B (17), IgM (15), C3 (11), and a special protein, Tuftsin (5). 
Others using different methods have found no difference in opsoniz-
ing capacities via the ACP between functionally splenectomized 
patients and normal children (22). These studies point out the 
problems associated with current assays for opsonic activity. 
Hill and workers (10) have shown that measurement of PMN 
chemiluminescence (CL) during phagocytosis of opsonized zymosan 
particles can be used to indirectly quantitate ACP opsonic activity. 
In this procedure, zymosan particles are opsonized in serum treated 
3 
++ 
with Mg - ethyleneglycol tetraactic acid (EGTA) to remove calcium 
thus blocking the classic complement pathway (6, 7, 10, 17). The 
opsonized zymosan particles are then mixed with a suspension of 
normal PMNs. As the PMNs phagocytize the particles, there is an 
increase in leukocyte hexose monophosphate shunt activity producing 
excited molecular oxygen and carbonyl groups. As these excited 
molecular forms relax to the ground state, photons are emitted which 
can be detected and quantitated using a liquid scintillation 
counter (1 2). 
In the present study, we have used this method to assess 
nonspecific opsonic activity in serum from 21 splenectomized Hodgkin's 
disease patients. A few patients were evaluated before surgery 
in order to eliminate the possibility of abnormal opsonic activity 
due to Hodgkin's disease. Additional patients were drawn at various 
intervals after surgery to monitor any changes in opsonic activity 
with time. Factor Band IgM levels have also been measured. 
CHAPTER 2 
METHODS AND MATERIALS 
Chemiluminescence was measured immediately following the 
addition of a suspension of normal PMNs to z}~osan particles which 
have been opsonized in fresh or fresh frozen, chelated or unchelated 
serum from patients and controls. Prior to opsonization, the z}~osan 
was washed and brought to proper concentration, and was refrigerated 
until the addition of serum and chelators. 
Factor Band IgM levels were tested on serum samples drawn 
simultaneously for the chemiluminescence procedure. These levels 
were measured using immunodiffusion techniques (Behring Diagnostics, 
Sommerville, N.J.) of some patients and controls. No further 
discussion of immunodiffusion techniques will be made since no 
modification of this procedure was made and the focus of this study 
was chemiluminescence. 
Serum 
Venous blood obtained from Hodgkin's disease patients and 
age-matched controls was allowed to clot over a 30 minute period. 
The serum was separated and stored immediately at -70°C until assay. 
Leukocyte Suspensions 
Heparinized (10 U/ml) whole venous blood was obtained from 
healthy adult donors. Leukocyte rich plasma was collected using 
S 
dextran sedimentation. The leukocyte rich plasma was centrifuged at 
1,000 rpm for 10 minutes, and the supernatant was removed. The 
remaining cell button was washed twice in sterile phosphate buffered 
saline (PBS), (pH 7.4) (4,SOO ml distilled water, S.2g Na2P04 , 0.9g 
KCl, 0.9 g KH2P04 , and 36g NaCl). The cell button was resuspended in 
PBS, counted using a hemacytometer, and adjusted to 1 x 107 PMN/ml. 
This suspension was prepared just prior to addition of zymosan. 
~osan Preparation 
Zymosan particles (Schwartz-Mann, Orangeburg, N.Y.) were 
washed once in sterile PBS and adjusted to a concentration of 
10mg/ml in PBS. One-half ml aliquots were dispensed in sterile 
12 x 7Smm plastic tubes (Falcon, Oxnard, Calif.) and centrifuged at 
2,000 rpm for 10 minutes. The PBS was removed, and the pellets were 
stored at 4°C for no longer than one week. 
Opsonization of Zymosan 
The zymosan pellet was reconstituted with O.Sml of freshly 
thawed unchelated serum or 0.4ml freshly thawed serum to which SOul 
of 100mM EGTA (Sigma, St. Louis, Mo.) and SOul of 10mM MgC1 2 were 
subsequently added. The tubes were rotated 1 hour at 37°C in a 
rotorack (Fisher Scientific, Santa Clara, Calif.). After rotation, 
zymosan was centrifuged at 2,000 rpm for 10 minutes. The serum was 
removed and replaced with O.Sml PBS. 
Quantitation of Chemiluminescence 
Two tenths ml of opsonized zymosan particles in PBS (lOmg/ml) 
were added to O.Sml of the leukocyte suspension (1 x 107 PMN/ml) 
and 2.8ml of PBS (total volume is 3.5ml) and placed scintillation 
vials wrapped in aluminum foil and stored in darkness for at least 
18 hours prior to use. Vials were immediately capped, mixed, 
and placed in a Beckman LS-100c scintillation counter (Fullerton, 
Calif.), out of phase, with one photomultiplier tube disconnected. 
Each reaction was counted starting at 1 minute for 1 minute at 
6 
10 minute intervals for a total of 60 to 90 minutes. Duplicate 
samples were counted for each patient and control serum. Vials of 
only zymosan particles opsonized by control serum in PBS were counted 
along with vials containing only leukocyte suspension in PBS. CL 
was expressed as mean counts per minute of duplicate vials. 




These findings will be divided into 3 parts each discussing 
an aspect of this investigation: ++ Influence of Mg -EGTA on 
chemiluminescence, relationship of opsonic activity to postsplenec-
tomy interval, and correlation of opsonic activity with Factor B 
and IgM levels. 
++ The effect of Mg -EGTA serum chelation on CL quantitation is 
illustrated in Figure 1. Actual accounts obtained from a representa-
tive patient and control are plotted against time. Lower peak CL 
++ 
values after treatment of Mg -EGTA are noted in both patient and 
control. The reason for this finding is unclear, but may indicate 
some contribution of the classic pathway to the opsonization of 
zymosan. 
Figure 1 also illustrates the baseline counts of the p~m 
suspension and the opsonized zymosan particle control. No peak in CL 
is evident in these suspensions when they are counted separately. 
In contrast, when zymosan and PMNs are mixed, a marked peak in CL 
occurs. The leukocyte suspension resulted in an average background 
+ 3 
count of 4.7 - 0.3 (SEM) x 10 cpm. The zymosan particles opsonized 




























Figure 1. Effect of Mg++-EGTA serum chelation on CL. 
CL counts are plotted against time. The solid lines indicate the 
control counts and the dotted lines indicate representative 
patient counts. The counts obtained in chelated samples are 
designated. The zymosan and cell background counts are shown 
in the lower portion of the figure. 
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3 0.3 (SEM) x 10 cpm. 
++ Figure 2 shows the effect of Mg -EGTA treatment on the 
kinetics of the CL peak. The average peak in CL occurred at approxi-
mately 25 minutes when zymosan was opsonized in untreated patient 
and control sera. ++ Mg -EGTA treatment markedly delayed the CL peak 
to approximately 55 minutes for both groups. Again, the reason for 
this apparent delay in kinetics is unclear. 
Relationship Activity to 
Pos 
No marked differences were noted between ACP opsonic activity 
of patient and control sera when all specimens were considered. 
When sera from patients categorized by postsplenectomy interval were 
considered, some differences were observed. In Figure 3, each 
patient's actual count was compared to the corresponding control and 
expressed as a percentage of control. The first group, presplenec-
tomy, did not differ from controls, l08.8%±4.6 (SEM). The second 
group consisting of patients from 10 to 31 days postsplenectomy 
showed a lower average peak CL value with a mean of 80.3% :4.6 (SEM). 
The second group consisting of patients from 10 to 31 days 
postsplenectomy showed a lower average peak CL value with a mean 
of 30.3%±2.6 (SEM). The controls for this group actually produced a 
somewhat higher mean value when compared to the other group controls. 
The reason for this is not evident but should be considered in 
evaluation of the results although CL is subject to some variance in 
counts between assays. The third group of patients were studied 32 














































Figure 2. Effect of Mg++-EGTA serum chelation on the kinetics 
of peak CL for patients and controls. Mg++-EGTA treated groups 
have a delayed appearance of the peak. 
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C 0 Group I Grou p 2 Group 3 Group 4 
Figure 3. CL peak values categorized as to time before and 
after splenectomy. The CL values are expressed as percent of the 
corresponding control peak values. The solid lines indicate the 
mean peak values and the dotted lines represent the SEM. 
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104.3%: 5.7 (SEM). A fourth group of patients from 1 to 6 years 
postsplenectomy were evaluated and produced a mean peak of 93%: 10.8 
(SEM). 
No large differences were apparent, therefore, between adult 
patients and controls more than 1 month after splenectomy. There 
were, however, 3 adolescent patients who exhibited persistently low 
opsonic activity. A twelve year old female had low CL activity for 
over 2 months postsplenectomy (Table 1). A 15 year old male exhibited 
a CL value of 71% of the corresponding control, 2 years postsplenec-
tomy; and, a 17 year old who had been splenectomized 5 years 
previously elicited a peak CL value of 49% of the control. 
Table 1 
CL Activity of Chelated Serum from a l2-year-old Hodgkin's 
Disease Patient Obtained at Various Intervals After 





of the Corresponding Control. 
9 days 31 days 63 days 
96% 71.2% 64.4% 
121 days 
103.8% 
Figure 4 depicts the kinetics of CL activity following mix-
++ ture of zymosan, opsonized by Mg -EGTA treated sera, and the 
leukocyte suspension. The results of splenectomized Hodgkin's 
disease patients are plotted with time following splenectomy and 
shown as percentage of their corresponding control time of peak CL. 
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- Time of Peak CL 
Prespl ene cf omy 10 days to 31 days 32 days to I yeaf I year fa 6 years 
Figure 4. The time to the peak appearance of CL activity. 
The patients were grouped as to the time pre and post splenectomy. 
The patient values are expressed as percent of the corresponding 
control time. The mean values for each group are plotted, and the 
SEM are indicated for each group by the extending solid lines. 
The dotted lines represent the mean CL peak values expressed as 
percent of control peak values. 
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delay in the appearance of that peak. This suggests that the 
kinetics proceeded at a lower rate in the patients. At the time 
after splenectomy when the CL peak returned to values comparable to 
control, there was no delay in the time of peak CL activity. 
With Factor Band IgM Levels 
Table 2 depicts the comparison of some CL values (expressed 
as percentages of control peak counts) with Factor Band IgM levels. 
No trends are evident in the comparison. Low CL values do not 
correspond low Factor B levels just as low levels do not corres-
pond with low CL values. 
Table 2 
The Correlation of CL Activity with Factor Band IgM Levels. 
CL Values are Expressed as Percent of the Corresponding 
Control Values. Normal Levels for Factor Bare 12-30 
mg/dl and Normal Levels for IgM are 60-299 mg/dl. 
CL 
% of Control Factor B IgM 
Value mg/dl mg/dl 
41.2 48.0 132 
71.0 81.6 20 
49.3 28.8 38 
71.3 23.0 102 
119 50.4 144 
121.9 21.6 26 
73.8 36.0 60 
88.4 78.4 108 
85 30.4 50 
130.4 25.2 66 
91.9 36.0 26 
163.7 102.4 50 
Normal CONTROL 1 21.6 66 




It has been shown that the incidence of overwhelming sepsis 
increases from 0.1% in the normal population to 11.5% in splenectom-
ized patients with reticuloendothelial diseases including Hodgkin's 
disease (16). Chilcote et al. has reported a 10% increase in the 
incidence of overwhelming postsplenectomy infections in a study of 
200 Hodgkin's disease children and adolescents (4). Others have 
reported an increased incidence of overwhelming sepsis in disorders 
associated with functional asplenia such as sickle cell anemia (11, 
12, 21). Johnston et al. (11) and Winklestein and Drachman (17) have 
proposed that sickle cell disease patients possess an inability to 
fully utilize the ACP during phagocytosis of S. pneumoniae which may 
explain, in part, the propensity to infection with this organism. 
The present studies suggest that there may be a slight 
depression of nonspecific opsonic activity for 10 to 31 days after 
splenectomy in Hodgkin's disease patients (Figure 3). Since the 
control group for this category did not correlate with other control 
groups, the validity of this finding should be questioned at this 
time; however, the question may be resolved with further study and a 
greater number of assays. Nevertheless, some comment should be made 
concerning the trends that have become evident during this study. 
16 
Opsonic activity of unchelated patients' sera did not differ 
appreciably from control activity as illustrated by peak value 
(Figure 1) or CL kinetics (Figure 2). Chelated serum samples from 
the same assays did show some differences which suggest that the 
mechanisms involved in the opsonization of zymosan with and without 
chelation are not well defined (6). 
Factor B levels obtained during this period of apparent 
depression of opsonic activity remained at control levels (Table 2). 
It has been previously shown by other investigators (10, 17) that 
low Factor B levels are associated with low ACP nonspecific opsonic 
activity in cord serum. However, in our population, no correlation 
was evident between Factor B levels and CL. I~1 levels also 
remained at normal levels in most cases which disagrees with previous 
work (15). Therefore, if the trend continues, it appears that some 
component(s) in the nonspecific activity of the ACP other than 
Factor B may be deficient for a period of time following splenectomy 
in Hodgkin's disease patients. 
Previous investigators have shown that the patient's age and 
time after splenectomy are both important factors in determining the 
susceptibility to overwhelming infection (20). The trends in our 
study suggest that the spleen may have an important role in the 
maintenance of some component(s) of the ACP and nonspecific opsoniza-
tion (Figure 3 and Table 2). 
During the period of study, none of the splenectomized 
Hodgkin's disease patients developed overwhelming infection. Although 
we have shown by an indirect measurement that a trend of abnormal 
17 
ACP nonspecific activity may exist in Hodgkin's disease patients 
following splenectomy, its significance in the observed susceptibility 
to infections remains to be determined. 
Summary 
This study indicates that splenectomy in Hodgkin's disease 
patients may cause depression in the nonspecific alternative comple-
ment pathway (ACP) opsonic activity for a period of time. The non-
specific ACP activity was measured indirectly by PHN chemilumines-
cence (CL) produced as the leukocytes phagocytize zymosan particles 
opsonized in chelated sera. A few patients drawn prior to surgery 
did not show the depression, and a few adolescent patients continued 
to have low CL values. Nonchelated sera did not result in such 
depressed activity. Factor Band IgM levels did not correlate with 
low CL values suggesting possible abnormalities in some other 
component(s) of the ACP. More study is indicated in order to confirm 
these trends. Since none of the splenectomized patients developed 
overwhelming infection during our study, additional investigations 
are necessary to more positively correlate these trends with the 
patients' propensity to overwhelming postsplenectomy infections. 
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